Company profile: Ashvattha Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage precision nanomedicines and PET imaging agents, developing D-4517.2 for wet AMD and DME, OP-801 targeting CNS macrophages/microglia as a biomarker of neuroinflammation, OP-101 to modulate inflammatory cell activity in severe COVID-19 and other inflammatory diseases, and CSF1R Dendranib, a CSF1R tyrosine kinase inhibitor for multiple sclerosis.
Products and services
- D-4517.2: A precision-engineered anti-angiogenic nanomedicine that crosses the blood-retinal barrier and targets activated ocular cells, used for treating wet AMD and diabetic macular edema
- OP-101: An immunomodulatory nanomedicine that targets regions of inflammation and modulates inflammatory cell activity, used for treating severe COVID-19 and other inflammatory diseases
- OP-801: A PET-compatible imaging agent that targets activated macrophages and microglia in the central nervous system, serving as a biomarker for neuroinflammation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ashvattha Therapeutics
Abionic
HQ: Switzerland
Website
- Description: Provider of point-of-care diagnostic solutions at the boundaries of medical technology, biotechnology and nanotechnology, including abioSCOPE for rapid, accurate results from a single drop of blood; PSP Sepsis Test using Pancreatic Stone Protein for early sepsis detection; saliva-based SARS-CoV-2 antigen test; aeroallergen specific IgE panel; ferritin test for iron deficiency; and cSOFA COVID-19 severity score for triage and management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abionic company profile →
Emergent BioSolutions
HQ: United States
Website
- Description: Provider of medical countermeasures for biological and chemical threats, developing, manufacturing, and delivering products including NARCAN® Nasal Spray to rapidly reverse opioid overdose; BioThrax® and CYFENDUS™ anthrax vaccines; ACAM2000® smallpox vaccine; TEMBEXA® antiviral for smallpox; and EbangaTM therapeutic antibody for Ebola virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emergent BioSolutions company profile →
Lumen Bioscience
HQ: United States
Website
- Description: Provider of biologic drug and vaccine development and manufacturing, leveraging a platform for rapid, cost-effective production. Pipeline includes biologic cocktails for C. difficile colitis, Covid-19 GI infection, and inflammatory bowel disease, a preclinical cardiometabolic program with Novo Nordisk, and a Phase 2 product candidate for traveler’s diarrhea backed by CARB-X and the Bill & Melinda Gates Foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumen Bioscience company profile →
Lumora
HQ: United Kingdom
Website
- Description: Provider of workflow-based molecular diagnostics solutions that simplify clinical diagnostics, industrial microbiology, and sample preparation, based on its proprietary BART Technology platform; developing an integrated testing station for gastrointestinal (GI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumora company profile →
ProStrakan
HQ: United Kingdom
Website
- Description: Provider of specialty pharmaceutical development and commercialisation of prescription medicines for unmet therapeutic needs in major markets; headquartered in Scotland with more than 300 employees and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProStrakan company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ashvattha Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ashvattha Therapeutics
2.2 - Growth funds investing in similar companies to Ashvattha Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ashvattha Therapeutics
4.2 - Public trading comparable groups for Ashvattha Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →